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Abstract 
Strategies for optimisation of 177Lu-octreotate therapy 
– exploring local administration and combination therapy regimens 
Viktor Sandblom 
Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska 
Cancer Center, Sahlgrenska Academy, University of Gothenburg, Sweden, 2019 
 
Neuroendocrine tumours (NETs) are a group of heterogeneous tumour types that originate in 
hormone-producing organs. Patients with NETs are often diagnosed after the primary tumour has 
metastasised. One treatment option for these patients that has shown very promising results is 
systemic treatment using the radiolabelled somatostatin analogue 177Lu-octreotate. However, the 
outcome of this treatment is currently restricted by healthy organs at risk. 
The aim of this work was to optimise 177Lu-octreotate therapy of NETs by investigating strategies 
based on local administration and on combination therapy regimens. 
The feasibility of local treatment of liver metastases was evaluated by administering 177Lu-octreotate 
via isolated hepatic perfusion (IHP) in a pig animal model. During IHP, the liver was completely 
isolated from the systemic circulation. An intraoperative gamma detector was evaluated for the 
purpose of determining 177Lu activity concentration in vivo during treatment. This detector was also 
evaluated by assessment of its technical performance parameters using phantoms. In summary, the 
results showed that it could be feasible to treat patients with liver metastases from NETs with 177Lu-
octreotate via IHP. A relatively inhomogeneous uptake was obtained and to accurately quantify 
177Lu activity concentration using an intraoperative gamma detector, measurements may need to be 
performed at several positions over the liver. 
In the combination therapy experiments, nude mice transplanted with NETs were treated with 
radiation therapy alone (as 177Lu-octreotate or external beam radiotherapy) and in combination with 
one of the drugs gemcitabine, vandetanib, cabozantinib, or ganetespib. After treatment, tumour 
volume was followed and compared with that in control mice. Overall, combination treatment 
resulted in the largest decrease in tumour volume and the longest time to progression. The results 
indicated that additive, and sometimes synergistic, effects could be obtained when combining 177Lu-
octreotate with another drug for treatment of patients with NETs. 
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 Sammanfattning på svenska 
Syftet med studierna i denna avhandling var att studera olika metoder för att 
förbättra målsökande strålbehandling med det radioaktiva läkemedlet 177Lu-
oktreotat (lutetium-177-oktreotat) för patienter med neuroendokrina tumörer.  
Neuroendokrina tumörer är en cancertyp som kan uppkomma i kroppens 
hormonproducerande organ, t.ex. i tarmkanalen, lungorna eller levern. Vad som 
utmärker neuroendokrina tumörer från andra cancertyper är att de har en stor 
mängd av en viss sorts receptorer på sin cellyta. Detta möjliggör målsökande 
strålbehandling genom injektion av det radioaktiva läkemedlet 177Lu-oktreotat. 
Läkemedlet består av två delar där radionukliden 177Lu står för själva strål-
behandlingen medan transportmolekylen oktreotat ser till att läkemedlet binder 
sig specifikt till neuroendokrina tumörceller. Ett problem vid behandlingen är att 
även friska organ i kroppen, främst njurar och benmärg, tar upp en viss mängd 
av läkemedlet, vilket kan leda till biverkningar om en för stor mängd ges. Denna 
begränsning gör det svårare att ge en tillräcklig mängd 177Lu-oktreotat för att helt 
kunna bota patienter. 
Studierna i denna avhandling har utförts som fem delarbeten. I arbete 1 och 2 
studerades en ny metod för att ge 177Lu-oktreotat-behandling lokalt till neuro-
endokrina tumörer i levern genom en s.k. isolerad leverperfusion där levern 
kirurgiskt kopplas bort från kroppens övriga blodcirkulation. Denna nya 
behandlingsmetod kan göra det möjligt att minimera upptag och biverkningar i 
friska organ. I arbete 1 utvärderades den tekniska prestandan för en strålnings-
detektor avsedd för mätning av stråldosen till levern och dess tumörer under 
pågående behandling. Denna detektor, och behandlingsmetoden i stort, 
utvärderades vidare i arbete 2 där en tänkt patientsituation simulerades genom att 
behandla en gris. 
I arbete 3, 4 och 5 studerades metoder där strålbehandling gavs tillsammans med 
ett av fyra icke-radioaktiva läkemedel i syfte att öka behandlingseffekten. Detta 
gjordes genom att behandla tumörbärande möss antingen med enbart strålning 
(som 177Lu-oktreotat eller extern strålbehandling) eller strålning i kombination 
med ett annat läkemedel för att sedan jämföra effekten av dessa behandlingar. 
Sammanfattningsvis visade resultaten att 1) isolerad leverperfusion med 177Lu-
oktreotat är en ny och lovande metod för att förbättra målsökande strålbehandling 
av neuroendokrina tumörer i levern, och 2) effekten av strålbehandling på neuro-
endokrin tumörvävnad kan ökas genom att kombinera behandlingen med ett 
annat läkemedel, både med avseende på tumörvolym och effektens varaktighet.
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1 Introduction 
This thesis focuses on two strategies for optimisation of 177Lu-octreotate therapy: 
1) local drug administration in order to spare healthy organs at risk, and 2) 
combination therapy regimens. 
1.1 Neuroendocrine tumours 
Neuroendocrine tumours (NETs) are a heterogeneous group of slow-growing 
tumour types that originate in the endocrine or nervous system [1, 2]. The most 
common site of origin is the gastrointestinal tract, followed by the lungs, pancreas, 
liver, thymus and thyroid. NETs often secrete a large amount of hormones 
resulting in the so-called carcinoid syndrome with diarrhea and flushing as 
common symptoms. Patients with NET experience a lower quality of life 
compared with the general population [3]. Because of the endocrine origin, NETs 
frequently overexpress somatostatin (SST) receptors (SSTRs) which can serve as 
molecular targets for systemic therapy [4, 5]. SSTRs occur in five different 
subtypes (SSTR1-5) and the relative expression of these subtypes can affect the 
choice of drug. 
The incidence of NETs has increased over the last few decades from about 1 to 
5 cases per 100,000 people, and is believed to be around 8 per 100,000 today [6]. 
Generally, the primary tumour is small and give relatively vague symptoms 
initially. Therefore, many patients have metastatic spread at the time of diagnosis 
and consequently a worse prognosis. The survival is strongly dependent on 
tumour stage and grade but also site of origin. It is difficult to give an exact 
number but reports on 5-year survival vary between about 50-80% and 20-60% 
for localised and metastatic disease, respectively [1, 6-8]. 
Small-intestine NETs (SI-NETs) constitute a type of NETs that often originate 
in the ileum of the small intestine [8, 9]. The characteristics of SI-NETs are similar 
to those associated with NETs in general, e.g., SSTR overexpression, slow growth 
rate, and vague initial symptoms. In addition to SSTRs, SI-NETs also express 
chromogranin A, synaptophysin, and serotonin, which can be used as indicators 
for the disease.  
Medullary thyroid cancer (MTC) is another example of a cancer that belongs to 
the family of NETs. There are several types of thyroid cancers, but only a small 
fraction (1-2%) of all thyroid cancers are diagnosed as medullary thyroid cancer 
[10]. In contrast to other types of thyroid cancer, MTC originates from the 
parafollicular C-cells of thyroid, resulting in a hormone-producing feature 
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characteristic for NETs. MTC can occur either sporadically or as a hereditary 
form often part of the so-called multiple endocrine neoplasia type 2 (MEN2) 
syndrome. In addition to overexpression of SSTRs, mutations in the proto-
oncogene rearranged during transfection (RET) is common in MTC, further 
enabling the use of targeted therapies [11]. 
1.1.1 Treatment of neuroendocrine tumours 
The primary treatment for patients with NETs is surgery and many patients are 
operated with curative intent [12]. However, due to the high prevalence of 
metastatic spread, additional treatment is needed for many patients. There are 
several treatment options for patients with metastatic disease. Most of these 
patients receive one or several types of systemic therapy following surgery. If the 
metastases are confined to the liver, some kind of liver-specific treatment can be 
an option. 
1.1.1.1 Liver-specific treatments 
The gastrointestinal tract is the most common site of origin for NETs. 
Consequently, metastatic spread to the liver is common because of the anatomical 
structure of the circulation system. For patients with liver-dominant disease, 
several liver-specific treatments are available, including trans-arterial embolisation 
(TAE) [13], trans-arterial chemoembolisation (TACE) [14], radioembolisation 
(RE) [15, 16], radiofrequency ablation (RFA) [17], and liver or multivisceral 
transplantation [18]. Most of these treatments utilise the fact that the liver has two 
main blood supplies – the hepatic artery and the portal vein – and that healthy 
liver tissue receives most of its blood and nutrients from the portal vein, while 
many malignancies, e.g. liver metastases from NETs, are instead mainly supplied 
by the hepatic artery. 
In TAE, also known as hepatic artery embolisation (HAE), the hepatic artery is 
occluded by injection of a blocking agent (e.g. plastic particles, glue, or metal coils) 
resulting in ischemia and necrosis in the tumours. TACE is similar to TAE, but 
instead of simply shutting of the blood supply, the blocking agent particles are 
also coated with a chemotherapeutic drug. Hence, when these particles are 
injected into the liver via the hepatic artery, the tumours will be attacked in several 
ways. Since the hepatic artery is used for the injection, the tumours will be more 
affected than the healthy normal tissue. The radiotherapeutic equivalent of TACE 
is RE, in which small radioactive glass or resin spheres (most commonly 
containing 90Y) are used instead of particles coated with chemotherapeutic drugs. 
These radioactive spheres lodge in the small vessels of the tumour resulting in 
local irradiation of the tumour cells. This treatment is also known as selective 
internal radiation therapy (SIRT) or trans-arterial radioembolisation (TARE). 
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Another option for treatment of liver metastases from NETs is RFA. Unlike the 
embolisation procedures described above, RFA is not based on the difference in 
blood supply for tumours and healthy liver tissue. Instead, a needle-like probe is 
placed inside each tumour to be treated and a radiofrequency alternating current 
is used to increase the temperature inside the tumour leading cell death. 
1.1.1.2 Systemic therapy 
When NETs have spread beyond the liver, which is not uncommon, some kind 
of systemic therapy is needed. Several systemic drugs are available for NETs but 
most of these are associated with side effects and sometimes the toxicity can 
overweigh the benefits of treatment. 
SST analogues have shown positive effects on symptom control for many NETs. 
Natural SST has a very short biological half-life in patients. Therefore, two long-
acting formulations of SST analogues have been developed and evaluated in 
clinical phase III studies, namely octreotide long-acting repeatable (LAR) and 
lanreotide autogel [19, 20]. These drugs show similar efficiency and are routinely 
used as first-line systemic treatment for many NETs today, especially for those 
that are functionally active [12]. 
Many other systemic drugs have also been evaluated for treatment of NETs. 
Interferon alpha can be used as second-line therapy after SST analogues, mainly 
for symptomatic control but it has also shown inhibition of tumour growth in 
some patients [21]. Telotristat ethyl is a more recent drug that can be used to 
reduce hormonal symptoms from NETs [22]. Everolimus is another option for 
treatment of NETs, especially for pancreatic NETs for which everolimus is 
recommended for first- or second-line treatment following the results of a large 
phase III study [23]. Furthermore, several tyrosine kinase inhibitors (TKIs) have 
shown very promising results in NETs, including sunitinib for pancreatic NETs 
as well as vandetanib and cabozantinib for MTC [24-26]. Vandetanib and 
cabozantinib are both approved by the Food and Drug Administration (FDA) for 
treatment of patients with metastatic MTC and also recommended by the 
American Thyroid Association (ATA) as single-agent first-line therapy in these 
patients [10]. 
Chemotherapy can also be a treatment option for patients with NETs even 
though one or several of the above mentioned targeted therapies are preferred. 
Chemotherapy are mainly used for more aggressive high-grade NETs or those 
that are SSTR negative. A combination of streptozotocin, doxorubicin and 5-
fluorouracil has been an established therapy but temozolomide with capecitabine 
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is now gaining popularity [27, 28]. Gemcitabine is another chemotherapeutic drug 
that has been evaluated both for MTC and other NETs [29-31]. 
Lastly, one of the most successful and promising systemic treatment options for 
patients with NETs is peptide receptor radionuclide therapy (PRRT) using 177Lu-
octreotate. In 2010, a large multicenter phase III trial was initiated. Preliminary 
results are now available which have led to the approval of 177Lu-octreotate for 
certain NETs. PRRT is described more in detail in chapter 1.2.1. 
1.2 Radionuclide therapy 
In radionuclide therapy, the ionising radiation emitted through the decay of 
radioactive atoms (also called radionuclides) is used to treat different medical 
conditions, e.g. cancer. The first systemic radionuclide therapy experiments were 
performed in 1913 by Frederick Proescher who injected patients with soluble 
radium salts [32]. A few decades later, new radionuclides were introduced. In 
1936, 32P and 24Na were first used to treat leukaemia and polycythaemia vera [33]. 
During the 1940s, 131I was first used for several thyroid-related conditions, e.g. 
hyperthyroidism and thyroid cancer. Some of these early examples of radionuclide 
therapy are still in clinical use today. 
The development of carrier molecules has been a landmark for radionuclide 
therapy. Early uses included monoclonal antibodies, which had a substantially 
lower specific uptake in tumours than many of the much smaller carrier molecules 
commonly used today. In the 1980s, after 131I had been chemically bound to 
metaiodobenzylguanidine (MIBG), the first clinical experiments of using 131I for 
treatment patients with NETs were performed [34, 35]. After 111In had been 
bound to the peptide octreotide in the early 1990s, and a high specific uptake of 
this compound in NETs had been demonstrated, the field of PRRT began to 
emerge [36, 37]. 
1.2.1 Peptide receptor radionuclide therapy 
PRRT is a term used to describe treatments in which radionuclides are bound to 
small peptides that bind with high affinity to SSTRs and used to treat NETs. Two 
commonly used peptides are the SST analogues octreotide and octreotate. These 
peptides are very similar but have minor differences in amino acid composition 
and octreotate has a higher affinity for SSTR2 [38]. The first clinical PRRT 
experiments were performed in the early 1990s using 111In-octreotide [39-41]. 
These early studies showed a favourable effect on hormone-related symptoms but 
tumour regression was rarely seen. A few years later, 111In was substituted by beta-
emitting radionuclides 90Y and 177Lu [42-44]. Initial therapeutic results of 90Y-
Viktor Sandblom 
5 
octreotide and 177Lu-octreotate were very encouraging and demonstrated 
improved rates of tumour regression compared with 111In-octreotide, as well as a 
reduction of the side effects previously associated with 111In-octreotide such as 
myelodysplastic syndrome and leukaemia. However, severe kidney toxicity was 
noted in some patients after 90Y-octreotide therapy which lead to the introduction 
of kidney-protecting agents for PRRT [45]. Following these developments, many 
patients have been successfully treated with 90Y-octreotide and 177Lu-octreotate 
over the past two decades. In recent years, 177Lu-octreotate have gained increasing 
popularity over 90Y-octreotide, partly because of the lower kidney toxicity 
associated with 177Lu-octreotate [46]. 
Today, 177Lu-octreotate (full name Lutetium-177-[DOTA0, Tyr3]-octreotate) 
therapy is a well-established treatment for patients with NETs in many centres 
worldwide [47-57]. Treatment is given according to a standardised protocol 
originally developed at the Erasmus Medical Center in Rotterdam [58]. First, to 
avoid saturation of SSTRs, systemic treatment with SST analogues is usually 
interrupted about 4-6 weeks before start of 177Lu-octreotate treatment. Then, 
177Lu-octreotate is given in cycles, with an interval of about 6-10 weeks between 
cycles, to allow bone marrow and other healthy organs at risk time to recover. 
During each cycle, 3.7 or 7.4 GBq 177Lu-octreotate is administered as an 
intravenous (i.v.) infusion over 30 minutes. To reduce the uptake in and exposure 
of the kidneys, positively charged amino acids, usually lysine and arginine, are 
administered together with the 177Lu-octreotate infusion. The number of cycles, 
and thus the total amount of 177Lu-octreotate, given to each patient is restricted 
by healthy organs at risk. Treatment is discontinued when the absorbed dose has 
reached 23-28 Gy to the kidneys or 2 Gy to the bone marrow, whichever comes 
first. This restriction usually results in 4-6 treatment cycles. 
177Lu-octreotate was recently approved, under the marketing name Lutathera®, 
for the treatment of patients with advanced metastatic midgut NETs both in the 
USA and in Europe. This approval followed the results of the first randomised 
controlled trial (NETTER-1). In that study, 177Lu-octreotate was compared to 
octreotide LAR (current first-line therapy for metastatic NETs) and demonstrated 
significantly prolonged progression-free survival (PFS) and improved quality of 
life [59, 60]. Final results on overall survival (OS) are not yet published. In the 
prescribing information for Lutathera®, a fixed treatment protocol including 4 
cycles of 7.4 GBq is specified. 
1.3 NET-related radionuclides 
When radionuclides are used for therapy, a high emission yield of particles with 
short range, e.g. electrons, and a low photon contribution is required to achieve a 
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high absorbed dose locally [61]. For example, the two most commonly used 
radionuclides for PRRT, 90Y and 177Lu, emit primarily electrons. Favourable 
properties for localisation and diagnosis can instead be achieved by using a 
radionuclide with a high emission yield of photons, or positrons resulting in 
annihilation photons. Until recently, a SPECT scan with 111In-octreotide has been 
the gold standard for image-based diagnosis of NETs [62]. This imaging 
technique is now being replaced by PET scans with 68Ga-labeled SST analogues 
due to their superior ability to detect NET lesions [63, 64]. Table 1 lists physical 
properties of the radionuclides most commonly used for diagnosis and/or 
treatment of NETs. 
Table 1. Physical properties of radionuclides most commonly used for diagnosis and/or treatment 
of NETs [65] 
   Average energy per decay (keV) 
Radionuclide 
Main 
purpose Half-life Electrons Positrons Photons 
68Ga Diagnosis 67.7 min 0.560 737 949 
90Y Therapy 2.67 d 933  <0.01 
111In Diagnosis 2.80 d 34.8  406 
177Lu Therapy 6.65 d 148  35.1 
 
1.4 Optimisation of 177Lu-octreotate therapy 
Even though 177Lu-octreotate therapy has shown a profound benefit for patients 
with NETs since its introduction, few patients achieve complete remission and 
optimisation of 177Lu-octreotate therapy is warranted. Several potential strategies 
for optimisation of PRRT have been suggested, e.g., methods to increase SSTR 
expression, choice of radionuclide and carrier molecule, the use of kidney-
blocking or radio-protecting agents, fractionation schedule, local administration, 
or combination therapy [66]. These strategies can be categorised into one of two 
main approaches, to 1) reduce side effects on healthy organs at risk, or 2) increase 
the therapeutic effect on tumour tissue. This thesis focuses on optimisation of 
177Lu-octreotate therapy by exploring two of the suggested strategies; namely local 
administration and combination therapy regimens. 
1.4.1 Local administration 
The main purpose of local administration is to reduce the exposure of healthy 
organs at risk. This can be especially useful for liver metastases from NETs. The 
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previously discussed liver-specific treatments are a few examples of local 
administration techniques. However, these methods are not based on PRRT. 
Intra-arterial injection directly into the liver is one technique that has been tested 
for PRRT [67, 68]. The goal of an intra-arterial injection is that a large part of the 
administered amount will bind to SSTRs in liver metastases during the first 
passage through the liver, leading to a reduced uptake in healthy organs at risk. 
To further reduce the systemic exposure, the technique of isolated hepatic 
perfusion (IHP) could be utilised. 
1.4.1.1 Isolated hepatic perfusion (IHP) 
During IHP, the liver is completely isolated from the systemic circulation, 
allowing high doses of drugs to be administered to the liver with minimal systemic 
exposure [69]. Before the isolated perfusion circuit is established, the femoral and 
external jugular veins are connected to an external pump creating a percutaneous 
bypass from the lower extremity around the liver. Then, the portal vein is clamped 
and the hepatic artery and the inferior caval vein are cannulated and connected to 
a heart-lung machine, isolating the liver from the systemic circulation (Figure 1). 
The liver can then be perfused by blood containing high concentrations of drugs. 
After 60 minutes, the liver is thoroughly rinsed and the procedure ends by 
restoration of the systemic circulation. Today, IHP with the chemotherapeutic 
drug melphalan is clinically used to treat liver metastases from malignant 
melanoma and colorectal cancer, but has also been evaluated for NETs [70-72]. 

Figure 1. Schematic overview of the setup for the IHP procedure. Illustration by Johanna Allerth 
IHP has not yet been used together with radionuclide therapy. This could now be 
possible due to the development of disposable components that prevent 
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radioactive contamination of the heart-lung machine. By administering 177Lu-
octreotate using the IHP technique in order to treat liver metastases from NETs, 
the exposure of kidneys and bone marrow (which are the main organs at risk for 
systemic 177Lu-octreotate therapy) might be strongly reduced. This administration 
technique would also lead to an increased concentration of 177Lu-octreotate in the 
blood circulating through the IHP circuit. For this proposed procedure, the 
healthy liver tissue would instead be the main organ at risk, because of the 
isolation from the systemic circulation and the high concentration of 177Lu-
octreotate present in the liver. Therefore, the absorbed dose to the liver has to be 
closely monitored so that the perfusion can be ended if needed to avoid negative 
side effects. It would also be important to determine the absorbed dose to liver 
metastases, as well as the exposure of organs and other tissues outside the isolated 
perfusion circuit, since a certain degree of leakage of 177Lu-octreotate could occur 
either during the IHP or after the liver has been reconnected to the systemic 
circulation. All this requires accurate quantification of 177Lu activity concentration 
in vivo. One option for this quantification could be to use an intraoperative 
gamma detector (IGD). 
IGDs are small hand-held instruments for detection of gamma radiation [73]. 
They are designed to be used for radioguided surgery, where the purpose is to 
find and surgically remove lesions during surgery after an injection of a diagnostic 
radiotracer based on e.g. 99mTc or 111In. One example of radioguided surgery is the 
location of NETs after an injection of 111In-octreotide [74, 75]. Since 177Lu emits 
both electrons and photons (Table 1), it is possible that 177Lu activity 
concentration could be quantified in vivo using an IGD. Over the last few 
decades, the technical performance of IGDs have been evaluated, such as 
sensitivity, response linearity, and spatial resolution [76-83]. However, most of 
these evaluations were made for diagnostic situations involving low amounts of 
activity of radionuclides other than 177Lu. For the proposed treatment technique 
of administering 177Lu using IHP, a much higher amount of activity would be 
used compared with the diagnostic situation.  
Before the proposed treatment technique can be used clinically for patients, it is 
important to evaluate the possibility of using IGD measurements to quantify 177Lu 
activity concentration in vivo in this therapeutic situation. As a first step, a 
technical performance evaluation by phantom measurements of 177Lu is needed. 
It will also be necessary to simulate the clinical situation in order to study uptake 
and distribution of 177Lu in healthy liver tissue, to estimate the radiation exposure 
of the staff involved, and to further evaluate the quantification ability of the IGD. 
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1.4.2 Combination therapy 
Combination therapy is a promising and growing area of PRRT optimisation [66]. 
When radiation interacts with a cell, it can deliver all or part of its energy to the 
deoxyribonucleic acid (DNA) in the cell nucleus, leading to radiation-induced 
DNA damage. These damages also occur indirectly when free radicals, created by 
the radiation, interacts with the DNA. Radiation-induced DNA damage is 
followed by cellular responses such as cell cycle arrest, DNA repair, senescence, 
apoptosis, and mitotic catastrophe [84]. If 177Lu-octreotate is combined with a 
substance that affect such responses, leading to an interaction between the effects 
of the two substances, it is possible that the anti-tumour effect from the ionising 
radiation can be increased in a synergistic manner. This interaction is usually 
referred to as radiosensitisation [85].  
Apart from potentially resulting in a synergistic anti-tumour effect, combination 
therapy can offer several important benefits for cancer patients (Figure 2) [86]. 
Firstly, if two drugs with different toxicity profiles are used, then the total amount 
of treatment can be increased compared with either monotherapy. Secondly, 
many cancer patients develop drug resistance with time, and for these patients, 
the switch to a new treatment can be an important next step in their treatment. 
Also, if two drugs are administered at the same time, it is possible that one of the 
drugs can inhibit development of resistance to the other. Thirdly, the use of 
multiple drugs could be crucial to be able to effectively treat heterogeneous 
tumours in which only part of the cells respond to a certain drug. The same 
argument can be made for multiple tumours within a patient, for example if liver 
metastases respond differently than bone metastases. Lastly, given that there is a 
large individual variation between patients, the use of combination therapy gives 
each patient a better chance that at least one drug will be effective [87]. 

Figure 2. Overview of some potential benefits of combination therapy [86, 87] 
Strategies for optimisation of 177Lu-octreotate therapy 
10 
There are several clinical examples of combination therapy involving PRRT for 
the treatment of NETs. One of the first combinations evaluated was 177Lu-
octreotate plus capecitabine [88-90]. The addition of temozolomide to this 
combination has also been evaluated [91, 92]. In some cases, the infusion of 5-
fluorouracil has been used instead of its oral prodrug capecitabine [50, 93]. Results 
indicate that combination therapy can increase PFS and OS compared with only 
PRRT. More recently, the combination of 177Lu-octreotate plus everolimus has 
also been evaluated but many patients required dose reduction or treatment 
discontinuation due to treatment-related side effects [94]. The development of 
new and efficient treatment combinations for NETs is important to further 
optimise the outcome of PRRT. In preclinical studies, many drugs are being 
evaluated in combination with radiation therapy for NETs and other cancer types. 
A few candidates are presented below. 
1.4.2.1 Gemcitabine 
Gemcitabine is a chemotherapeutical nucleoside analogue that has shown anti-
tumour effect in many cancer types including MTC [30, 95]. The mechanism of 
action for gemcitabine starts with activation by phosphorylation resulting in the 
active metabolites gemcitabine diphosphate and triphosphate [96, 97]. These 
metabolites are responsible for the cytotoxic effect by incorporation in the DNA 
during DNA synthesis leading to cell cycle arrest or apoptosis, and by interfering 
with the enzyme ribonucleotide reductase involved in DNA synthesis and repair. 
In preclinical studies, gemcitabine has a well-documented radiosensitising effect 
on many cancer types [98-102]. The combination of external beam radiotherapy 
(EBRT) and gemcitabine has also been evaluated in many clinical studies, most 
commonly for pancreatic cancer [103-107]. Therefore, gemcitabine is an 
interesting candidate for combination therapy with PRRT for NETs. 
1.4.2.2 Vandetanib and cabozantinib 
Vandetanib and cabozantinib are targeted drugs belonging to the family of TKIs. 
One target for these drugs is the RET proto-oncogene, frequently mutated in 
MTC [11]. In addition, vandetanib and cabozantinib also target receptors for the 
signal protein vascular endothelial growth factor (VEGF) which are commonly 
overexpressed in MTC [108]. Inhibition of tyrosine kinases related to these targets 
leads to the main anti-tumour effect. 
As previously mentioned, vandetanib and cabozantinib are both approved for 
systemic treatment of metastatic MTC following the results of two large phase III 
trials [24, 25]. Given the promising clinical results and the recommendation by 
the ATA of using vandetanib and/or cabozantinib as first-line systemic therapy 
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for metastatic MTC [10], it would be very interesting to evaluate the possibility of 
achieving an increased effect on MTC by combination therapy with PRRT. 
1.4.2.3 Ganetespib 
Ganetespib is a novel targeted drug acting as an inhibitor of heat shock protein 
(HSP) 90 [109]. HSP90 is a molecular chaperone that regulates normal folding, 
stability, and function of proteins [110]. Some of these proteins are required for 
tumour cell survival and growth, and consequently, HSP90 is upregulated in 
several types of cancer [111, 112]. Therefore, inhibition of HSP90 offers a new 
and promising therapeutic approach for cancer therapy. 
Ganetespib is currently being evaluated in clinical trials. Results from several 
recent phase I-II trials including various cancer types show that ganetespib is 
associated with manageable toxicity and preliminary disease control rates (stable 
disease or better response) of about 25-30% [113-116]. In many preclinical 
studies, ganetespib has been shown to have a radiosensitising effect in various 
cancer cell lines [117-120]. Further investigations of this radiosensitising effect in 
NETs would be interesting in order to evaluate ganetespib for combination 
therapy with PRRT. 
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2 Aims 
The overall aim of this work was to investigate strategies to optimise 177Lu-
octreotate therapy of neuroendocrine tumours based on local administration 
(Papers I-II) and on combination therapy regimens (Papers III-V). 
The specific aims were: 
• to evaluate the ability of two intraoperative gamma detectors to 
quantify 177Lu activity concentration in vivo by measuring 
performance parameters, such as sensitivity, response linearity, 
and spatial resolution, using phantoms (Paper I) 
 
• to evaluate the feasibility of using 177Lu-octreotate therapy 
administered via isolated hepatic perfusion by simulating the 
clinical situation in a pig model (Paper II) 
 
• to investigate the effect of combining radiation treatment with 
gemcitabine for medullary thyroid cancer in a mouse model 
(Paper III) 
 
• to investigate the effect of combining radiation treatment with 
tyrosine kinase inhibitors vandetanib or cabozantinib for 
medullary thyroid cancer in a mouse model (Paper IV) 
 
• to investigate the effect of combining 177Lu-octreotate 
treatment with ganetespib for small-intestine neuroendocrine 
tumours in a mouse model (Paper V) 
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3 Materials and Methods 
3.1 Radiopharmaceutical (Papers I-III and V) 
177Lu-octreotate was prepared according to the manufacturer’s instructions (IDB 
Holland BV, the Netherlands). The fraction of peptide-bound 177Lu was 
determined by instant thin layer chromatography (ITLC SG, PALL Corporation, 
USA). This fraction was over 99% in all experiments. The stock solution of 177Lu-
octreotate was diluted using saline solution to the desired concentration for each 
experiment. 177Lu activity was determined using a well-type ionisation chamber 
(CRC-15R, Capintec, USA). 
3.2 Local administration of 177Lu-octreotate (Papers I-II) 
By administering 177Lu-octreotate via IHP, the uptake in and exposure of healthy 
organs at risk could be strongly reduced. To evaluate whether an IGD could be 
used to estimate 177Lu activity concentration in tissues during this proposed 
procedure, performance parameters of two commercially available IGDs were 
assessed using phantoms containing 177Lu. To further evaluate the feasibility of 
the proposed procedure, a clinical situation was simulated using a pig model. 
3.2.1 Phantom measurements (Paper I) 
Measurements were performed using sources and phantoms containing 177Lu. 
The performance parameters examined were response linearity, sensitivity, spatial 
resolution and its depth dependence, organ thickness dependence, and tumour 
detectability. 
The two IGDs evaluated were the Gamma Finder II (World of Medicine GmbH, 
Germany) and the Navigator GPS (Dilon Diagnostics, USA), hereafter called 
detector A and B, respectively. Detector A is a scintillation detector containing a 
CsI(Tl) crystal and detector B is a semiconductor detector containing a CdTe 
crystal. Both detectors are equipped with tungsten collimators. Detailed 
dimensions of the detectors can be seen in Figure 3. Detector A has a non-
adjustable low-energy threshold of 110 keV. Detector B has a set of pre-defined 
energy windows suited for measurements of different diagnostic radionuclides 
(99mTc, 111In, 125I, and 131I). A 20% energy window centered over the 99mTc peak 
at 141 keV (range 112-169 keV) was used for all detector B measurements. 
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
Figure 3. Schematic view of the geometrical design of the two IGDs evaluated. Information about 
the distance from the crystal to the end of the collimator was not available for detector A, indicated 
by the question mark and the arrow inside the crystal. Distances in mm. Figure adapted with 
modification from Paper I 
Response linearity and sensitivity was assessed using point sources of increasing 
activity. For each activity, the count rate as counts per second (cps) was 
determined. The sensitivity was calculated as the slope of the trend line fitted to 
the data obtained. 
Spatial resolution and its depth dependence was assessed using a line source 
placed at different depths (0-80 mm) in a block phantom of tissue-equivalent 
plastic. The detector was placed at the surface of the phantom and moved 
perpendicularly across the line source. The spatial resolution was determined as 
full-width-at-half-maximum (FWHM) of the line profiles obtained. 
Organ thickness dependence was assessed using a gel phantom consisting of a 
stack of 2% agarose gel blocks containing a homogeneous activity distribution. 
The detector was placed at the surface of the gel phantom and the count rate for 
different thicknesses (10-150 mm) was determined. 
Tumour detectability was assessed using a tumour phantom created by placing a 
gel sphere (simulating a tumour) at the surface of the gel phantom described 
above (simulating the background). The tumour spheres (5-20 mm diameter) 
contained 2-30 times higher activity concentration than the background blocks, 
and values were assumed to be relevant for clinical situations [121, 122]. The 
number of counts over the tumour sphere (CT) and over the background (CBgr) 
was measured (Figure 4). 
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
Figure 4. Measurement setup for the assessment of tumour detectability. Figure adapted with 
modification from Paper I 
For the assessments of organ thickness dependence and tumour detectability, 
statistical analyses were performed to find statistically significant differences 
between two given signal intensities, C1 and C2. The standard deviation (SD) of 
the difference between the signals, Ƴ&1-C2), was calculated: 
 ߪ(ܥଵ െ ܥଶ) = ඥܥଵ + ܥଶ (1) 
Then, differences between C1 and C2 were considered statistically significant 
(p<0.05) if they exceeded two SDs of the difference, i.e. if C1-C2 > 2×Ƴ&1-C2). 
For the assessment of organ thickness, the signal intensity at each thickness was 
compared with the signal intensity at the largest thickness (150 mm). For the 
assessment of tumour detectability, CT was compared with CBgr for each tumour-
to-background ratio and tumour size. 
3.2.2 Simulation of the clinical situation (Paper II) 
To simulate the clinical situation, a healthy pig was prepared for surgery. The IHP 
procedure was performed ex vivo to avoid any potential risk of contaminating the 
entire pig. After the liver had been connected to a heart-lung machine, it was 
removed and placed in a bowl and the pig was euthanised. The perfusion circuit 
was established according to a standard IHP procedure with one exception – the 
portal vein was used for the perfusion instead of the hepatic artery [69]. The 
perfusion was started and once a steady blood flow had been established, 490 
MBq 177Lu-octreotate was added to the system. After 60 minutes, the perfusion 
was stopped and the liver was rinsed with Ringer’s solution (Ringer Acetat, Baxter 
Medical AB, Sweden). This study was approved by the Ethical Committee on 
Animal Experiments in Gothenburg, Sweden. 
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During the perfusion and rinsing, two detectors were used to monitor 177Lu 
activity concentration. Detector B was positioned over the liver and a collimated 
NaI(Tl) scintillation detector (Scintibloc type 51 SL 12 no. 7775, Saint-Gobain 
S.A., France) connected to a locally developed software (MedicView, Systemdata, 
Sweden) was positioned over the circuit tube (Figure 5). In addition, all staff 
members present in the operating room wore personal dosimeters (Harshaw 
TLD, Thermo Scientific, USA) registering both whole body and extremity 
exposure. A hand-held intensimeter (RNI 10/SR Intensimeter, Nuklidtech 
Sweden AB, Sweden) was used to measure the exposure environment at locations 
where a high radiation dose rate was expected. 

Figure 5. Experimental setup for the IHP simulation. The blood reservoir was sealed inside a 10 
mm thick lead cylinder (not shown). The circuit included an injection port for safe administration 
of substances into the system 
After the perfusion, the activity distribution in the liver was examined by 
SPECT/CT imaging (Discovery NM/CT 670, GE Healthcare, United Kingdom) 
and the fused SPECT/CT images were analysed using Xeleris Workstation (GE 
Healthcare). 
Lastly, detector B was used to estimate the activity concentration at 20 positions 
over the liver which were then compared with the activity concentration in 
biopsies sampled in the corresponding locations (Figure 6). The activity 
concentration estimated by detector B was calculated based on the measured 
count rate using data from the phantom measurements of organ thickness 
dependence as a calibration. The activity concentration in the biopsies were 
determined by measurements in a gamma counter (Wallac 1480 Wizard 3”, Wallac 
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Oy, Finland). Then, 30 additional biopsies were sampled and measured to further 
investigate the homogeneity of 177Lu-octreotate distribution. 

Figure 6. Detector B was used to estimate activity concentration at 20 positions after the IHP 
which were then compared with the activity concentration in corresponding biopsies 
3.3 Combination therapy studies (Papers III-V) 
Nude mice transplanted with patient-derived NETs were treated with different 
schedules of radiation therapy (as 177Lu-octreotate or EBRT) and/or a drug. The 
drugs used were gemcitabine (Paper III), vandetanib and cabozantinib (Paper IV), 
and ganetespib (Paper V). All experiments were approved by the Ethical 
Committee on Animal Experiments in Gothenburg, Sweden. 
3.3.1 NET animal models 
Two NET animal models were used for the combination therapy studies, namely 
nude mice carrying GOT1 (Paper V) or GOT2 (Papers III-IV) tumours. GOT1 
is an SI-NET cell line derived from a surgically removed liver metastasis of a 
patient [123]. The GOT2 cells were derived from a patient with sporadic MTC 
and transplanted to nude mice [124].  
For the experiments, female BALB/c nude mice (Charles River Laboratories, 
Germany and Janvier Labs, France) were subcutaneously transplanted with small 
tumour samples of GOT1 or GOT2 (1x1x1 mm3) under anaesthesia 
(Ketaminol® vet., Intervet AB, Sweden and Domitor® vet., Orion Pharma AB 
Animal Health, Sweden). Animals had free access to water and autoclaved food.  
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3.3.2 Radiation therapy 
Radiation therapy was given as 177Lu-octreotate (Papers III and V) or EBRT 
(Papers III and IV). 177Lu-octreotate was administered by i.v. injection in the tail 
vein. EBRT was performed using a Varian linear accelerator with a 6 MV photon 
beam using a 30x30 mm2 irradiation field (Varian Medical Systems, USA). The 
animals were anaesthetised and placed on their side on a tissue-equivalent 
polystyrene bed. Tissue-equivalent material was fitted around the tumour so that 
the centre of the tumour was at isocenter. 
3.3.3 Drugs 
Gemcitabine (Active Biochem LTD, China) was dissolved in saline solution and 
administered by intraperitoneal (i.p.) injection (Paper III). Vandetanib (Active 
Biochem LTD) was dissolved in a solution of PBS (Thermo Fisher Scientific, 
USA) and 1% polysorbate 80 (TWEEN® 80, Sigma-Aldrich, USA) and given by 
oral administration (Paper IV). Cabozantinib (Active Biochem LTD) was 
dissolved in sterile water and given by oral administration (Paper IV). Ganetespib 
(Selleckchem, Germany) was dissolved in a solution of sterile water, 5% DMSO, 
and 45% PEG and administered by i.v. injection in the tail vein (Paper V). 
3.3.4 Treatment schedules and follow-up 
Mice bearing GOT1 or GOT2 tumours were divided into groups of 5-12 mice 
per group and treated with different schedules of radiation therapy and/or a drug. 
The 177Lu activity, absorbed dose and amount of drug were chosen to give a low 
to moderate effect as monotherapy to enable detection of any increased effects in 
the combination therapy groups. A detailed overview is given in Table 2. 
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After start of treatment, the length, width, and height of the tumours were 
measured twice weekly using digital callipers, and the tumour volume was 
calculated by assuming an ellipsoidal shape. At the end of each study, the mice 
were killed by cardiac puncture under anaesthesia (Pentobarbitalnatrium vet., 
Apotek Produktion & Laboratorier, Sweden). Before that, a mouse was killed if 
the tumour reached a volume corresponding to more than 10% of the body 
weight, if the body weight was reduced by more than 10%, or if the mouse showed 
any signs a poor general condition. 
3.3.5 Internal dosimetry 
The absorbed dose to tumours was calculated for the animals that received 177Lu-
octreotate (Papers III and V). The administered activity was determined by 
measuring the activity in each syringe before and after injection. The absorbed 
dose, D, was calculated using the Medical Internal Radiation Dose (MIRD) 
formalism [125]: 
 
𝐷𝐷 = Ã∑𝑖𝑖𝐸𝐸𝑖𝑖𝑌𝑌𝑖𝑖𝜙𝜙𝑖𝑖
𝑀𝑀
, (2) 
where Ã is the time-integrated activity, the product EiYi is the energy emitted per 
decay, 𝜙𝜙i is the absorbed fraction, and M is the mass of the tumour. Only the 
contribution from electrons was considered. Therefore, ∑EiYi was set to 147.9 
keV and 𝜙𝜙i was set to 1 [65, 126]. Ã was estimated from previously published data 
on biodistribution of 177Lu-octreotate in nude mice carrying GOT1 or GOT2 
tumours [127, 128]. 
3.3.6 Immunohistochemistry 
Tumours were fixed in formalin, dehydrated, embedded in paraffin, sliced into 
sections, and stained with haematoxylin and eosin (H&E) for morphological 
examination. Some sections were stained with Masson’s trichrome (MT) to 
analyse fibrosis (Paper III).  
For immunohistochemical (IHC) analysis, tumour sections were placed on glass 
slides and treated with EnVision™ FLEX Target Retrieval Solution (high pH) 
using a PT-Link (Dako, Denmark). IHC staining was performed using an 
Autostainer Link with EnVision™ FLEX (Dako). The following primary 
antibodies were used: Ki67 (AB9260, Merck Millipore, USA), chromogranin A 
(ab68271, Abcam and EP1030Y, Abcam), synaptophysin (ab16659, Abcam and 
SP11, Abcam), calcitonin (A0576, Dako), serotonin (LS-B7118, LSBio, USA), 
pan-cytokeratin (AE1/AE3, Dako), SSTR2A (UMB-1, Abcam), and HSP90 
(EPR3953, Abcam). Positive and negative controls were included in each run. 
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Tumour sections from animals treated with EBRT and/or gemcitabine stained 
for Ki67 and MT (Paper III) were digitalised and quantitatively analysed using an 
in-house developed MATLAB tool (R2017a, MathWorks, USA). By applying 
colour-thresholds, positively stained tissue could be segmented. Each section was 
divided into necrotic and viable tumour. Then, after excluding areas of 
background and artefacts, Ki67 staining was quantified in viable tumour, and MT 
staining (for collagen) was quantified for the entire tumour section. 
3.3.7 Statistical analyses 
To evaluate differences in tumour growth after start of treatment, group-wise 
mean relative tumour volumes (RTVs) were used for statistical analyses (Papers 
III-IV). RTV was individually defined as the tumour volume at a given time 
divided by the volume at treatment start. One-way ANOVA (GraphPad Prism 
7.04, GraphPad Software, USA) was used to analyse overall differences between 
groups. Then, Student’s t test with Bonferroni-Holm correction was used for 
group-to-group comparisons [129]. 
To analyse the potentially increased effect from combination therapy, the Bliss 
independence model was used to calculate a predicted additive effect based on 
the measured effects from monotherapy [130, 131]. Then, the measured effect in 
a combination therapy group was assumed to have been antagonistic, additive or 
synergistic if it was smaller than, equal to or larger than the predicted additive 
effect, respectively. 
Note that for the results presented here, these above-mentioned statistical 
methods were applied also for the tumour-volume data from the combination 
therapy experiments involving ganetespib, while different statistical methods were 
used to analyse the interaction effect in the article (Paper V). 
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4 Results 
4.1 Local administration (Papers I-II) 
4.1.1 Phantom measurements (Paper I) 
The two IGDs evaluated showed great differences in response (Figure 7). For 
detector A, the sensitivity and maximum measurable activity was 1200 cps/MBq 
and 6.1 MBq, respectively. The corresponding values for detector B was 500 
cps/MBq and 28 MBq. Furthermore, the response was linear (within ±10%) for 
activities up to 1.3 and 12 MBq for detectors A and B, respectively.  

Figure 7. Detector response for point sources of different activities. Figure re-used from Paper I 
Detector B had better spatial resolution than detector A (Figure 8). The largest 
relative difference in FWHM was 38% (at 20-mm depth). Furthermore, the 
response markedly decreased with increased depth of the line source for both 
detectors. At 10 mm depth, the response was 37% and 46% of the response at 0 
mm for detector A and B, respectively. 
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
Figure 8. Detector response for the 177Lu line source located at a depth of 0-80 mm. Spatial 
resolution is given as FWHM. Figure adapted with modification from Paper I 
The evaluations of organs thickness dependence showed that the response 
increased with increasing thickness up to about 100 mm, after which a plateau 
was reached, for both detectors (Figure 9). 

Figure 9. Organ thickness dependence of the detectors. The stars indicate the largest thickness 
where a statistically significant difference in count rate was found when compared with 148 mm. 
Figure re-used from Paper I 
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Regarding tumour detectability, detector B showed somewhat higher CT/CBgr 
ratios (Figure 10). However, the situations where a statistically significant 
difference between CT and CBgr was found were the same for both detectors. 

Figure 10. Tumour detectability given as the ratio between the count rate over a simulated tumour 
(CT) and background (CBgr). The stars indicate that a statistically significant difference was found 
between CT and CBgr. Figure re-used from Paper I 
4.1.2 Simulation of the clinical situation (Paper II) 
The radioactivity measurements during the IHP showed a fast increase of 177Lu 
in the liver and a maximum was reached after about 10-15 minutes. When the 
rinsing was started, a fast decrease in count rate was seen, reaching a plateau after 
about 10-20 minutes. However, about 25% of the 177Lu remained in the liver after 
the rinsing was finished. Furthermore, the SPECT/CT image (acquired after the 
perfusion and rinsing) revealed a relatively inhomogeneous distribution of 177Lu 
in the liver with a coefficient of variation (CV=SD/mean) of 77% (Figure 11). 
An inhomogeneity was also seen in the 50 biopsies with a CV=36%. 

Figure 11. SPECT/CT image of the liver showing three different cross sections of the voxel with 
the highest value (indicated by the red cross)
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After the IHP procedure and SPECT/CT imaging, the IGD (detector B) was 
used to estimate 177Lu activity concentration (CIGD) at several positions over the 
liver and the values were compared with biopsy measurements (CB). Overall, the 
two methods showed a good agreement (Pearson’s r=0.714 and p<0.001; Figure 
12). The ratio between the activity concentrations measured with the two methods 
(CIGD/CB) ranged from 0.54 to 1.45 (mean=0.93, SEM=0.06). 
 
Figure 12. Activity concentration in the liver estimated by the IGD (CIGD) vs. that in the biopsy 
(CB) in the same position. R2 is the coefficient of determination 
None of the personal dosimeters worn by the staff during the IHP procedure 
gave any measureable radiation dose at readout. The highest ambient equivalent 
dose rates in the operating room were measured close to the liver. At the surface 
of the liver, the dose rate was 100 μSv/h, with corresponding values 10 and 4 
μSv/h at 20 and 50-cm distance, respectively. 
4.2 Combination therapy (Papers III-V) 
4.2.1 Absorbed doses 
Treatment with 177Lu-octreotate resulted in absorbed doses of 0.13 Gy for GOT2 
mice injected with 10 MBq (Paper III) and 2.7 Gy for GOT1 mice injected with 
15 MBq (Paper V). As previously mentioned, the absorbed doses from EBRT 
were 5 Gy (Paper III) and 3 Gy (Paper IV). 
4.2.2 Tumour growth 
Given as monotherapy, all treatments resulted in clear effects on tumour volume 
compared with control even though suboptimal doses were deliberately chosen, 
except for 177Lu-octreotate treatment in GOT2 mice (Paper III) which resulted in 
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a response similar to that of control (Figure 13). Generally, minimum RTVs were 
reached after about 10-20 days. For example, the smallest RTV for the animals 
that received monotherapy with vandetanib and cabozantinib was 0.98 
(RTV/RTVcontrol=0.51, p<0.001) and 0.79 (RTV/RTVcontrol=0.44, p<0.001), 
respectively, at day 10 (Paper IV). Furthermore, EBRT monotherapy of GOT2 
mice (Papers III-IV) and 177Lu-octreotate monotherapy of GOT1 mice (Paper V), 
resulted in minimum RTVs of 0.57 (RTV/RTVcontrol=0.29, p<0.001, day 13) and 
0.93 (RTV/RTVcontrol=0.61, p=0.023, day 10), respectively.  
 
Figure 13. Tumour growth for nude mice trans-
planted with patient-derived NETs and treated
with radiation therapy as 177Lu-octreotate (177Lu) 
or external beam radiotherapy (EBRT) and/or
either gemcitabine (Gem), vandetanib (Vand),
cabozantinib (Cabo), or ganetespib (Gane). For
each treatment combination, the calculated
relative tumour volumes given a predicted
additive effect are shown. Stars indicate an 
overall statistically significant difference between
all group means (ANOVA). Error bars show
SEM. GOT2 was used in part A-D (Papers III-
IV). GOT1 was used in part E (Paper V) 
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In all experiments, the largest reduction in tumour volume was seen for the 
animals that received combination therapy. In some experiments, the measured 
effect from combination therapy even appeared to be larger than the predicted 
additive effects, specifically in the experiments of EBRT plus gemcitabine (Paper 
III, Figure 13B) and 177Lu-octreotate plus ganetespib (Paper V, Figure 13E). The 
measured effects of combining radiation therapy with TKIs vandetanib or 
cabozantinib appeared to be similar to the predicted additive effects (Paper IV, 
Figure 13C and D). The combination of 177Lu-octreotate and gemcitabine resulted 
in similar effect as gemcitabine monotherapy (Paper III, Figure 13A). 
4.2.3 Time to progression 
Most treatments initially resulted in tumour volume reduction or tumour growth 
inhibition. However, regardless of given treatment, the tumours started to regrow 
after a certain time, even when treatment was continuously administered during 
the entire follow-up. Tumour progression was defined to occur when a tumour 
was larger than at start of treatment or when an animal was killed, and curves of 
progression-free survival in all experiments are shown in Figure 14. All treatments 
resulted in a prolonged time to progression compared with control (except for 
177Lu-octreotate monotherapy in GOT2 mice, Paper III). Tumour progression 
for the control animals was generally reached after about 0-10 days. The time to 
progression for the treated animals varied substantially with treatment from about 
10 to 50 days, and in some cases, tumour progression had not been reached at the 
end of follow-up. Overall, combination therapy generally resulted in a longer time 
to progression than both monotherapy and control. 
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

4.2.4 Immunohistochemistry 
The GOT1 and GOT2 tumours used in this study had maintained characteristics 
of NETs. All tumours stained for SI-NET or MTC markers showed a high and 
specific expression of all markers (chromogranin A, synaptophysin, calcitonin, 
serotonin, and pan-cytokeratin), verifying the origin of the GOT1 and GOT2 
tumours (Figure 15). In addition, the GOT1 tumours also stained strongly for 
HSP90 and SSTR subtype 2.  
Figure 14. Time to progression for nude mice 
transplanted with patient-derived tumours and 
treated with radiation therapy as 177Lu-octreotate 
(177Lu) or external beam radiotherapy (EBRT) 
and/or either gemcitabine (Gem), vandetanib 
(Vand), cabozantinib (Cabo), or ganetespib 
(Gane). Note the difference in x-axis scale. 
GOT2 was used in part A-D (Papers III-IV). 
GOT1 was used in part E (Paper V) 
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Figure 15. Morphology of two representative tumours from untreated control groups showing 
neuroendocrine differentiation with strong IHC staining for MTC and/or SI-NET markers 
chromogranin A (CgA), synaptophysin (Syn), and calcitonin (Ctn). A) GOT2 (Paper IV), and B) 
GOT1 (Paper V). The GOT1 tumours also stained strongly for HSP90 and SSTR subtype 2. Figure 
adapted with modification from Paper V 
The quantification of Ki67 and MT staining in the sections of tumours harvested 
at the end of follow-up (day 30-58) after the experiments of EBRT in combination 
with gemcitabine (Paper III) showed overall a similar degree of staining in all 
tumours (Figure 16). The overall median was 64% and 3.0% for Ki67 and MT, 
respectively. However, several tumours that received treatment had a higher 
degree of MT-positive staining (of about 5-8%) than all untreated tumours which 
were similar to the overall median. 

Figure 16. Quantitative results of Ki67 (brown) and MT (purple) staining analysed for the animals 
treated with 5 Gy external beam radiotherapy (EBRT) and/or 60 mg/kg gemcitabine (Gem low), 
and their corresponding untreated controls. T=follow-up time 
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5 Discussion 
Radionuclide therapy with 177Lu-octreotate is a promising treatment option for 
patients with metastatic NETs. However, because of the current standardised 
treatment protocol, few patients achieve complete response after 177Lu-octreotate 
therapy. Several possible options for treatment optimisation exist. The main goal 
is to increase the effect on tumour tissue and/or to reduce side effects in healthy 
organs at risk. This could be achieved by investigating the optimal amount of 
peptide and activity per administration, optimal fractionation schedule, new radio-
protecting or kidney-blocking agents, tolerance doses for healthy tissue, methods 
to increase SSTR expression, techniques for local administration, or combination 
therapy [66]. For example, tumour SSTR expression and uptake could be 
increased by pre-treatment with a small amount of 177Lu-octreotate, a so-called 
priming administration [128]. There is also data showing that the amount of 
peptide and activity affects the uptake and biodistribution in both tumours and 
normal tissues [132, 133]. It is possible that the total amount of administered 
activity given according to the standardised treatment protocol can be increased 
[56, 134]. With increased knowledge, individual treatment planning could be 
performed, taking into account individual differences in biodistribution and 
radiation sensitivity of tumours and healthy organs. In this thesis, optimisation 
methods based on local administration and combination therapy were 
investigated. 
5.1 Local administration (Papers I-II) 
The purpose of a local administration is to increase the uptake of the 
radiopharmaceutical in a tissue of interest, e.g. a tumour, and to reduce the uptake 
in healthy organs at risk. Administration of 177Lu-octreotate via IHP is a novel 
technique suggested for local treatment of liver metastases from NETs. 
Compared with a systemic administration, this technique should result in a 
substantially reduced uptake in tissues and organs outside the isolated liver circuit, 
based on knowledge from the clinically established IHP procedure, where 
melphalan is used to treat liver metastases from melanoma [72]. As previously 
mentioned, there are other techniques for local treatment of liver metastases from 
NETs, e.g. RE and intra-arterial PRRT [67, 68, 135]. However, since these local 
treatments are given with the systemic circulation intact, they differ substantially 
from the technique of 177Lu-octreotate therapy during IHP, where the liver would 
be completely isolated during treatment. 
One major drawback of local treatment of liver metastases is that it is only feasible 
for patients with metastatic spread confined to the liver. In addition, the primary 
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tumour must have been removed completely during surgery (something that is 
often possible). However, for patients that fulfil these criteria, the administration 
of 177Lu-octreotate via IHP could be a very useful treatment option. Another 
limitation of this new technique is that the uptake of 177Lu-octreotate in healthy 
liver tissue would not be reduced as it would for tissues and organs outside the 
isolated liver circuit. If this treatment should be used for patients, close attention 
must be given to the uptake and activity concentration in healthy liver tissue.  
For systemic 177Lu-octreotate therapy, the kidneys and the bone marrow are the 
main organs at risk, and the tolerance doses of these organs have therefore 
received far more attention than that of the liver. Data from EBRT and RE with 
90Y microspheres suggest that the tolerance dose of the liver strongly depends on 
the volume irradiated [136, 137]. In a review summarising data from EBRT, 
absorbed doses to the liver that resulted in less than 5% of patients developing 
with severe side effects were 40-80, 30-50, and 25-35 Gy if 1/3, 2/3, and the 
entire liver volume was irradiated, respectively [137]. These values are similar to 
those presented in the 1991 landmark article on tolerance doses from EBRT by 
Emami et al. [138]. On the other hand, clinical studies on 90Y-RE suggest that 
absorbed doses to the whole liver of up to 100 Gy, or even more, can be safely 
given to patients [139-141]. Furthermore, for systemic 177Lu-octreotate therapy, 
liver toxicity is extremely rare, and for this treatment, the mean absorbed dose to 
the liver is about 0.2-0.6 Gy/GBq, resulting in a total absorbed dose of about 6-
30 Gy after 4-6 treatment cycles of 7.4 GBq [43, 48, 89, 142-144]. Altogether, the 
tolerance dose of the liver after 177Lu-octreotate therapy given via IHP might be 
substantially higher than the values of about 30 Gy suggested for EBRT. 
To be able to estimate the absorbed dose to healthy liver and NET liver 
metastases, information about absorbed fractions, organ masses, and biokinetics, 
both during and after IHP, is needed [125]. The results from the clinical 
simulation (Paper II) suggest that a certain amount of 177Lu-octreotate will remain 
in the liver after the IHP and rinsing is finished. The activity concentration in liver 
and metastases after IHP could be determined using a gamma camera at different 
times after treatment (e.g. day 7 and 14). The biological half-life of 177Lu-octreotate 
in liver tissue should be about 2-4 days [145-147]. There are several possible 
explanations to why a certain amount (about 25%) of 177Lu-octreotate remained 
in the liver after the IHP simulation. Since neither hepatocytes nor hepatic stellate 
cells express SSTRs, one explanation could be difficulties in achieving a sufficient 
rinsing in all parts of the liver [148]. This would also explain the inhomogeneous 
activity distribution seen in the SPECT/CT images. It is also possible that part of 
the 177Lu-octreotate had bound to SSTRs expressed by phagocytic Kupffer cells, 
hepatic lymphocytes, or by cells in the bile ducts [148, 149]. 
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Determination of activity concentration also during IHP is important for 
estimations of absorbed doses. It should be possible to determine the activity 
concentration in vivo with satisfactory accuracy using an IGD if it is handled 
correctly and if certain factors are taken into account. The phantom 
measurements (Paper I) revealed dead-time effects at high activities for both 
IGDs evaluated that affected their response linearity and lead to a maximum 
measureable activity. In a therapeutic situation, high amounts of activity will be 
involved. Therefore, adding extra collimation to reduce the sensitivity could be 
beneficial to avoid reaching the maximum measureable activity. Extra collimation 
would also increase the spatial resolution. Furthermore, an organ thickness 
dependence was seen for both IGDs. This thickness dependence can be corrected 
for if the response curve is known. Therefore, it is important to calibrate IGDs 
by phantom measurements to be able to translate a measured count rate into an 
activity concentration. When using such a calibration, it is important to account 
for potential high-uptake regions at deeper locations. Lastly, since a relatively 
inhomogeneous uptake in healthy liver tissue was obtained after the IHP 
simulation, measurements at several positions over the liver might be needed to 
be able to correctly estimate the mean absorbed dose in a clinical situation. Based 
on the activity concentration values determined by an IGD (detector B) compared 
with those in the corresponding biopsies (CIGD/CB values), the uncertainty in an 
IGD-determined activity concentration at a given position over the liver is about 
±50%. The total uncertainty in a calculated mean absorbed dose to the liver is 
estimated to be about ±60% (assuming independency between the individual 
uncertainties) [150]. However, if an inhomogeneous activity distribution is 
obtained also in a clinical situation, certain regions of the liver could receive higher 
doses than the calculated mean absorbed dose. The uncertainty in determining 
the activity concentration in a given tumour should be much lower than for 
healthy liver tissue, especially if the tumour is superficial and its size is similar to 
the field-of-view (FOV) of the IGD. 
The radiation exposure of staff during an IHP procedure, that would involve 
relatively high amounts of 177Lu-octreotate, should be possible to keep below 
regulatory limits. During the IHP simulation, all staff members could be 
positioned at a distance and often behind protective screens throughout most of 
the procedure, and consequently, no personal radiation doses were recorded. The 
same is possible in a clinical situation but one major difference exists. In a clinical 
situation, the surgeon must remove all tubes and close the surgical field. This 
would lead to a certain degree of radiation exposure, but based on the 
environmental exposure measurements during the IHP simulation, the total 
personal dose received after one procedure should be around 25 μSv. In Sweden, 
the annual dose limit for staff is 20 mSv, a limit that would be reached after about 
800 procedures [151]. 
Viktor Sandblom 
33 
There are limitations of the IHP simulation and the IGD evaluations. Firstly, the 
IHP simulation was performed ex vivo. The ex vivo setting was chosen because 
even a very low contamination of the pig would result in logistic problems when 
handling the carcass after the experiment. However, based on previous 
knowledge and experience from the standard IHP procedure with melphalan, the 
ex vivo perfusion should not have affected the results obtained [69]. Another 
limitation was that the simulation was carried out as a terminal experiment in 
which the systemic circulation was not re-established after the perfusion and 
rinsing were finished. It would be valuable to have included this part in the 
simulation to investigate potential leakage of 177Lu-octreotate to other organs 
outside the isolated circulation. Since the effect of rinsing on the decrease in 177Lu 
activity concentration appeared to wear off after about 10-20 minutes, re-
establishing the systemic circulation should not have led to any substantial leakage 
to other organs. However, this must be closely monitored if the technique of 
administering 177Lu-octreotate via IHP is used clinically. A third limitation is that 
the results of the IHP simulation are based on an experiment including only one 
pig. The simulation could be repeated to investigate if similar uptake and 
distribution of 177Lu-octreotate during and after IHP would be obtained. Lastly, 
the count rate over the liver (representing the activity concentration) during the 
IHP and rinsing was measured at a fixed position using the IGD. The main focus 
of this measurement was on biokinetics and the fixed position was used to avoid 
uncertainties due to positioning. However, given the inhomogeneity revealed by 
the SPECT images, and the narrow FOV of the IGD, measurements at several 
positions or the use of another detector could have provided valuable information 
during the IHP and rinsing. 
5.2 Combination therapy (Papers III-V) 
Combination treatment is another approach for optimisation of 177Lu-octreotate 
therapy investigated in this thesis. The main goal of combination therapy is to 
achieve an increased anti-tumour effect compared with either treatment alone. 
Ideally, a synergistic effect would be achieved but combination therapy can be 
useful also at additive levels, especially if two drugs with different toxicity profiles 
are used. 
When selecting drugs to use in combination with irradiation for treatment of 
NETs, many potential options exist. The drugs used for the combination therapy 
experiments (Papers III-V) were chosen for different reasons. Gemcitabine was 
chosen mainly because of the well-documented radiosensitising effect in other 
cancer types [96]. In addition, previous studies have shown that SSTR expression 
could be upregulated by gemcitabine [152, 153]. TKIs vandetanib and 
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cabozantinib were chosen because of their promising clinical results and because 
of the approval of these drugs for systemic treatment of metastatic MTC [24, 25]. 
Ganetespib was selected based on the results of a large-scale drug screening 
performed as a part of Paper V. Two cell lines derived from SI-NETs (GOT1 
and P-STS) were screened using a drug library consisting of 1224 inhibitors alone 
or in combination with EBRT. The screening revealed that HSP90 inhibitors 
could potentiate the anti-tumour effect from radiation in SI-NETs. In addition, 
ganetespib has shown promising radiosensitising effects in other cancer types and 
is one of the most clinically successful HSP90 inhibitors [117-120, 154]. 
The radiation-drug-combinations evaluated within the work of this thesis revealed 
increased anti-tumour effects that appeared to be either additive or synergistic 
depending on the drug used. Gemcitabine appeared to synergistically potentiate 
the effect of radiation therapy on patient-derived MTC tumours in nude mice 
(Paper III). The mechanism behind a potential synergistic effect could be related 
to alterations in cellular response to radiation-induced DNA damage caused by 
gemcitabine. After entering the cell, gemcitabine acts as a nucleoside analogue of 
cytidine and its active metabolites are incorporated into the DNA which can lead 
to inhibition of DNA damage repair [96]. In addition, gemcitabine interferes with 
the enzyme ribonucleotide reductase involved in DNA synthesis and repair. 
Another drug that appeared to synergistically potentiate radiation therapy is 
HSP90 inhibitor ganetespib (Paper V). HSP90 regulates many client proteins that 
are involved in proliferation, survival, oncogenesis and cancer progression [154]. 
Therefore, cancer cells rely on a high expression of HSP90 and are sensitive to 
HSP90 inhibitors. Inhibition of HSP90 has been shown to predominantly target 
components of the cellular DNA damage response [155]. The mechanisms 
behind a synergistic interaction between radiation therapy and inhibition of 
HSP90 have been suggested to be related to downregulation of DNA repair and 
cell growth oncoproteins as well as cell cycle checkpoint activation [156-158]. 
Lastly, combination therapy using irradiation and TKIs vandetanib/cabozantinib 
resulted in increased anti-tumour effects (Paper IV). These effects appeared to be 
additive, rather than synergistic, but the results still provide a useful option for 
optimisation of 177Lu-octreotate therapy, especially since the toxicity profiles for 
vandetanib/cabozantinib and 177Lu-octreotate are somewhat different. The main 
side effects associated with vandetanib and cabozantinib are related to the 
gastrointestinal system [24, 25], while the main side effects for 177Lu-octreotate 
therapy are haematological toxicity (usually reversible) and late renal toxicity [134, 
159]. In addition, both TKI treatment and 177Lu-octreotate therapy are already in 
clinical use for patients with MTC. 
In some of the combination therapy experiments included in this thesis, EBRT 
was used instead of 177Lu-octreotate. Specifically, EBRT was used for GOT2 
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tumours to obtain an absorbed dose sufficiently high to result in the desired 
tumour-volume reduction. The absorbed dose from EBRT was 3 or 5 Gy. 177Lu-
octreotate treatment of GOT1 tumours resulted in a similar absorbed dose of 2.7 
Gy, while the absorbed dose for GOT2 tumours after injection of 177Lu-otreotate 
was much lower – only 0.13 Gy. Both EBRT of GOT2 tumours and 177Lu-
octreotate treatment of GOT1 tumours resulted in clear reductions in tumour 
volume. It is likely that similar effects would have been seen also for 177Lu-
octreotate treatment of GOT2 if a higher absorbed dose would have been 
achieved. However, there is a lack of MTC animal models with a sufficiently high 
uptake of 177Lu-octreotate [127]. Therefore, EBRT was used for GOT2 tumours 
to be able to investigate potential interaction effects of combination therapy 
involving radiation on MTC, and to demonstrate that MTC is sensitive to 
irradiation. Clinically, there is a large variation in SSTR expression between 
patients with MTC but many patients demonstrate a much higher tumour uptake 
than available MTC animal models with tumour-to-blood activity concentration 
ratios of up to 350, compared with about 25-50 for GOT2 tumours [121, 127, 
160]. Furthermore, 177Lu-octreoate has been used to treat MTC in several clinical 
studies [161-166]. The treatment outcome has varied between studies but, 
generally, 177Lu-octreotate has proven to be a safe and effective treatment with 
response rates of about 40-70%. However, using one of the combination therapy 
strategies investigated here, the treatment outcome could be improved. 
Two different NET animal models were used for the combination therapy 
experiments – nude mice carrying GOT1 (SI-NET) or GOT2 (MTC) tumours 
[123, 124]. These animal models provide valuable possibilities to study 
combination therapy strategies for NETs. There are other animal models available 
but the options are limited [66]. The following cell lines are all derived from 
human NETs or tumours with NET features and can be transplanted to nude 
mice in order to study different treatment effects in vivo. TT is an SSTR-
expressing MTC cell line [167]. For example, vandetanib has shown clear anti-
tumour effects by targeting RET in an animal model carrying TT tumours [168]. 
KRJ-I is a cell line established from an SI-NET [169]. However, this cell line has 
recently been shown to not display a neuroendocrine phenotype [170]. BON is a 
pancreatic NET cell line established from a lymph node metastasis [171]. IMR-
32, CLB-BAR and CLB-GEMO are three SSTR-expressing neuroblastoma cell 
lines that have shown a high uptake of 177Lu-octreotate in vivo [172]. There are 
also two lung cancer cell lines available, small cell lung cancer cell line NCI-H69 
and bronchial NET cell line NCI-H727, and 177Lu-octreotate therapy has been 
successfully used in animals carrying tumours from these cell lines [173-175].  
Clinically, the most commonly used combination therapies involving PRRT are 
177Lu-octreotate in combination with capecitabine and/or temozolomide [88-91]. 
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Many other drugs are being evaluated in preclinical studies as new and interesting 
candidates for combination therapy with 177Lu-octreotate, e.g., inhibitors of poly 
[ADP-ribose] polymerase 1 (PARP-1), nicotinamide phosphoribosyltransferase 
(NAMPT), HSP90, or Hedgehog. Olaparib is a PARP-1 inhibitor that has been 
shown to potentiate the anti-tumour effect of 177Lu-octreotate in vitro (human 
osteosarcoma U2OS cells and rat pancreatic CA20948 cells) and ex vivo (patient-
derived pancreatic NET tissue) by modulation of the DNA damage response 
leading to an increased number of double strand breaks [176]. GMX1778 is a 
NAMPT inhibitor (closely related to PARP-1) that increased the anti-tumour 
effect of 177Lu-octreotate treatment in a study on nude mice carrying GOT1 
tumours, both in regard to tumour-volume reduction and the duration of the 
effect [177]. Olanespib is a HSP90 inhibitor that displayed synergistic effects in 
combination with 177Lu-octreotate in a 3D tumour spheroid model of NET cell 
lines [178]. The radiosensitising effect of this combination was also confirmed in 
vivo with low toxicity [179]. Sonidegib is a Hedgehog inhibitor that has been used 
in combination with 177Lu-octreotate to treat nude mice carrying GOT1 tumours 
[180]. Combination treatment lead to profound reduction in tumour volume and 
a prolonged time to progression. Additionally, gene expression analysis revealed 
several cancer-related signalling pathways that were affected by the combination 
therapy indicating a functional interaction between 177Lu-octreotate and 
sonidegib. The combination of 177Lu-octreotate and everolimus (inhibitor of 
mammalian target of rapamycin, mTOR) is an approach that has shown less 
promising results. In preclinical in vivo studies on animals carrying human small 
cell lung cancer NCI-H69 tumours or rat pancreatic AR42J or CA20948 tumours, 
combination treatment resulted in anti-tumour effects less than or similar to the 
effects from 177Lu-octreotate alone [181, 182]. Interestingly, combination 
treatment instead promoted formation of metastases, an effect that was not seen 
in control or 177Lu-octreotate-treated animals [181]. Everolimus plus 177Lu-
octreotate therapy has also been evaluated for NETs in a clinical phase I study 
and many patients required dose reduction or treatment cessation [94]. 
There are limitations of the combination therapy studies included in this thesis. 
Firstly, the treatment groups within each experiment did not contain the same 
number of animals, and in some cases, the number of animals per group was 
relatively low. This is a result of the fact that the animal models used are practically 
difficult to work with. For example, the tumour take-rate and growth after 
transplantation is very unpredictable. It is difficult to plan experiments in full 
detail regarding, e.g., number of mice per group, age of the mice, time between 
transplantation and start of treatment, tumour size at treatment start, or follow-
up time. In order to keep such factors as similar as possible between treatment 
groups, each experiment were carried out in several smaller parts. Another 
limitation was that the dose-response for each monotherapy was not closely 
Viktor Sandblom 
37 
evaluated. Even if the absorbed doses and administered amounts were chosen to 
result in moderate effects, a certain variation in the effect of monotherapy was 
seen between experiments. Information about an appropriate dose/amount was 
available from similar experiments for some treatments, but in some cases, a small 
pilot experiment was performed. Since different doses/amounts were used for 
different treatments, and since maximum therapeutic effects were most likely not 
reached, it is difficult to compare the treatments regarding which treatment had 
the largest anti-tumour effect. However, the deliberate use of suboptimal 
doses/amounts enabled analysis of the interaction effects when two treatments 
were combined, which was the main aim of these experiments. Higher 
doses/amounts would probably have led to larger therapeutic effects with 
possible cure in some animals. 
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6 Conclusions 
Radionuclide therapy with 177Lu-octreotate has proven to be a very successful 
treatment option for patients with neuroendocrine tumours since its introduction. 
However, complete response is rare and there is room for optimisation. In this 
work, two strategies for optimisation of 177Lu-octreotate therapy were explored: 
1) local drug administration (Papers I-II), and 2) combination therapy (Papers III-
V). The main conclusions are summarised as follows. 
Acceptable results were obtained for both intraoperative gamma detectors 
evaluated by phantom measurements (Paper I). The evaluations demonstrated 
factors that have to be corrected for, e.g. organ thickness and dead-time effects. 
Nevertheless, intraoperative gamma detector measurements could be used to 
determine 177Lu activity concentration in vivo with reasonable accuracy. 
It can be possible to treat patients with liver metastases from neuroendocrine 
tumours by administering 177Lu-octreotate via isolated hepatic perfusion (Paper 
II). However, to account for a potentially inhomogeneous distribution of 177Lu-
octreotate in healthy liver tissue, intraoperative gamma detector measurements 
may need to be performed at several positions over the liver to more correctly 
determine the activity concentration. 
Gemcitabine increased the anti-tumour effect of radiation therapy in mice 
carrying patient-derived medullary thyroid cancer, GOT2 (Paper III). The 
interaction between the effects of respective monotherapy appeared to act in a 
synergistic manner. 
Combination therapy using tyrosine kinase inhibitors vandetanib or cabozantinib 
and external beam radiotherapy resulted in increased therapeutic effects in mice 
carrying patient-derived medullary thyroid cancer, GOT2 (Paper IV). It is likely 
that similar combinatorial effects would be achieved if 177Lu-octreotate is used 
instead of external beam radiotherapy. 
Ganetespib increased the anti-tumour effect of 177Lu-octreotate treatment in mice 
carrying patient-derived small-intestine neuroendocrine tumours, GOT1 (Paper 
V). The interaction between the effects of respective monotherapy appeared to 
act in a synergistic manner. 
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7 Future perspectives 
In this thesis, different aspects of 177Lu-octreotate therapy optimisation were 
investigated by experimental studies based on local administration or combination 
therapy. The results of these studies demonstrated interesting options for 
optimisation that should be further evaluated in future studies. 
The combined use of 177Lu-octreotate therapy and IHP was successfully simulated 
ex vivo using a pig model. Future studies should evaluate this new treatment 
technique in patients with metastatic spread of NETs confined to the liver. The 
process of acquiring ethical approval for conducting such studies is currently on-
going. When first implementing this treatment clinically, close attention must be 
given to potential side effects in healthy liver tissue. Measurements of the activity 
concentration during and after the IHP procedure is crucial to estimate the 
absorbed dose to healthy liver in order to determine which amount of 177Lu-
octreotate that can be safely administered to patients. It will also be important to 
monitor potential leakage to organs outside the isolated circuit, especially after the 
systemic circulation has been re-established. 
Several drugs were demonstrated to result in favourable anti-tumour effects when 
combined with radiation therapy in nude mice carrying patient-derived NETs. 
These drugs could be administered in combination with 177Lu-octreotate in order 
to treat patients with metastatic NETs. Before proceeding to clinical use, further 
preclinical studies should investigate potential short-term and long-term side 
effects of these treatment combinations in healthy tissues. It will also be important 
to investigate the optimal administration schedule for each of these treatment 
combinations in preclinical studies. Important parameters of an optimal 
administration schedule include administered amount, number of fractions (a 
single or several administrations), time between fractions, order in which the 
treatments should be administered, and time between start of respective 
treatment. The optimal administration schedule should be chosen to maximise 
the anti-tumour effect while still keeping side effects at an acceptable level. 
Following these preclinical investigations, the most promising combination 
treatment protocols should be evaluated in patients with NETs. 
Lastly, 177Lu-octreotate therapy could be further optimised by combining the two 
strategies investigated. It would be very interesting to investigate the potential of 
administering 177Lu-octreotate in combination with another drug by IHP to treat 
patient with liver metastases from NETs.
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